Unnamed: 0,title,date,stock,sentiment
211098.0,80 Biggest Movers From Yesterday,2020-06-11 05:00:00-04:00,CANF,neutral
211099.0,61 Stocks Moving In Wednesday's Mid-Day Session,2020-06-10 13:31:00-04:00,CANF,neutral
211100.0,Can-Fite BioPharma Reports 3.902M ADS For $2.05/ADS,2020-06-10 08:02:00-04:00,CANF,neutral
211101.0,Following Pre-IND Guidance From FDA Can-Fite To Advance Piclidenoson Into Phase II COVID-19 Trial In The US,2020-06-09 07:04:00-04:00,CANF,neutral
211102.0,"Can-Fite Participating in BIO Digital International Convention And One-on-One Partnering Meetings On June 8-12, 2020",2020-06-08 07:26:00-04:00,CANF,neutral
211103.0,"Can Fite Says Following Meetings With FDA And EMA, Co To Submit Protocol,Conduct 1 Pivotal Trial For Registration In Both Markets For Namodenoson",2020-06-04 07:19:00-04:00,CANF,neutral
211104.0,Can Fite Biofarma shares are trading lower after the company reported worse-than-expected Q1 sales results.,2020-06-01 09:06:00-04:00,CANF,neutral
211105.0,"Can-Fite Biopharma Q1 EPS $(0.03) Beats $(0.66) Estimate, Sales $198.00K Miss $1.18M Estimate",2020-06-01 07:09:00-04:00,CANF,negative
211106.0,96 Biggest Movers From Yesterday,2020-05-27 04:20:00-04:00,CANF,neutral
211107.0,61 Stocks Moving In Tuesday's Mid-Day Session,2020-05-26 12:29:00-04:00,CANF,neutral
211108.0,28 Stocks Moving in Tuesday's Pre-Market Session,2020-05-26 07:18:00-04:00,CANF,neutral
211109.0,71 Biggest Movers From Friday,2020-05-26 04:30:00-04:00,CANF,neutral
211110.0,Can Fite Biofarma shares are trading higher after the company received a notice of allowance for Namodenoson patent in treatment of NASH and NAFLD.,2020-05-21 07:34:00-04:00,CANF,positive
211111.0,"Can-Fite Reports Receives Notice Of Allowance For Namodenoson Patent In Treatment Of NASH, NAFLD From US PTO",2020-05-21 07:03:00-04:00,CANF,neutral
211112.0,Can-Fite BioPharma Reports Pre-Investigational New Drug Application Submission To FDA For Piclidenoson In Treatment Of Coronavirus-Infected Patients With Moderate-To-Severe Symptoms,2020-05-15 07:02:00-04:00,CANF,neutral
211113.0,95 Biggest Movers From Friday,2020-04-20 05:00:00-04:00,CANF,neutral
211114.0,58 Stocks Moving In Friday's Mid-Day Session,2020-04-17 12:31:00-04:00,CANF,neutral
211115.0,70 Biggest Movers From Yesterday,2020-04-17 04:53:00-04:00,CANF,neutral
211116.0,52 Stocks Moving In Thursday's Mid-Day Session,2020-04-16 12:58:00-04:00,CANF,neutral
211117.0,52 Stocks Moving In Thursday's Mid-Day Session,2020-04-16 12:57:00-04:00,CANF,neutral
211118.0,33 Stocks Moving in Thursday's Pre-Market Session,2020-04-16 07:19:00-04:00,CANF,neutral
211119.0,86 Biggest Movers From Yesterday,2020-04-14 05:19:00-04:00,CANF,negative
211120.0,Mid-Afternoon Market Update: Crude Oil Up 2%; Biocept Shares Surge,2020-04-13 14:33:00-04:00,CANF,negative
211121.0,63 Stocks Moving In Monday's Mid-Day Session,2020-04-13 12:35:00-04:00,CANF,neutral
211122.0,Mid-Day Market Update: Dow Falls Over 500 Points; SCWorx Shares Spike Higher,2020-04-13 12:25:00-04:00,CANF,positive
211123.0,"Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics",2020-04-13 09:54:00-04:00,CANF,neutral
211124.0,"Can Fite Biofarma shares are trading higher after the company announced it has received approval to initiate a pilot clinical study of its drug candidate, Piclidenoson, for the treatment of moderate-to-severe symptoms in coronavirus infected patients.",2020-04-13 07:22:00-04:00,CANF,positive
211125.0,30 Stocks Moving in Monday's Pre-Market Session,2020-04-13 06:56:00-04:00,CANF,neutral
211126.0,"Can-Fite BioPharma Receives Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately",2020-04-13 06:30:00-04:00,CANF,positive
211127.0,Why Can-Fite's Stock Is Moving Higher Today,2020-04-07 11:56:00-04:00,CANF,neutral
211128.0,"Can Fite Biofarma shares are trading higher after the company announced it significantly achieved its main study endpoint in phase 2 NASH Study with Namodenoson were dose-dependent. UPDATE: Shares have since reversed, now lower.",2020-04-07 09:15:00-04:00,CANF,positive
211129.0,"Can-Fite Reports Main Study Endpoints In Phase 2 NASH Study With Namodenoson Were Dose Dependent, Significantly Achieved",2020-04-07 09:03:00-04:00,CANF,neutral
211130.0,"CanFite Shares Spike To Session High, Up 19%; Traders Circulate Apr. 3-Dated ClinicalTrials.gov Study Record Detail For Piclidenoson For Coronavirus Infection",2020-04-03 15:15:00-04:00,CANF,positive
211131.0,Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020,2020-03-30 07:05:00-04:00,CANF,neutral
211132.0,The Week In Cannabis: Marijuana Stocks Outperform S&P Again As Weed Is Deemed 'Essential' In COVID-19 Times,2020-03-28 16:12:00-04:00,CANF,neutral
211133.0,"Can-Fite Posts $9.6M Net Loss, Provides Clinical Trials Updates",2020-03-27 12:17:00-04:00,CANF,negative
211134.0,"Can-Fite Biopharma FY19 Net Loss $9.5M vs $6.6M In FY18, Sales $2M vs $3.8M In FY18",2020-03-27 07:07:00-04:00,CANF,negative
211135.0,Can-Fite Submits its Piclidenoson for Compassionate Use Treatment for Coronavirus Patients in Israel,2020-03-23 07:48:00-04:00,CANF,positive
211136.0,Can-Fite to Participate In Digital Bio-Europe Spring Partnering Conference; Says Looks To Partner On Co-Development Of Piclidenoson For Coronavirus Treatment,2020-03-18 07:05:00-04:00,CANF,neutral
211137.0,"The Week In Cannabis: Coronavirus Drop, Major Financing Agreements, Psychedelics Getting Hot",2020-03-14 08:53:00-04:00,CANF,neutral
211138.0,"The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals",2020-03-13 10:53:00-04:00,CANF,neutral
211139.0,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Mar. 13, 2020: GLD, OPK, IBIO, CPB, CANF",2020-03-13 08:13:00-04:00,CANF,positive
211140.0,30 Stocks Moving in Friday's Pre-Market Session,2020-03-13 07:32:00-04:00,CANF,neutral
211141.0,Can-Fite Reports Will Explore Anti-Coronavirus Effects Of Piclidenoson In Collaboration With Lewis Katz School Of Medicine,2020-03-13 07:07:00-04:00,CANF,neutral
211142.0,Can-Fite Says Preclinical Study Shows That Small Amounts Of CBD Can Help With Obesity,2020-03-11 15:21:00-04:00,CANF,positive
211143.0,Can-Fite Highlights PRe-Clinical Data Demonstrating 'Inhibition of Fat Cell Expansion by Cannabis Derived CBD',2020-03-11 07:32:00-04:00,CANF,negative
211144.0,101 Biggest Movers From Yesterday,2020-03-06 04:28:00-05:00,CANF,neutral
211145.0,Mid-Afternoon Market Update: Dow Tumbles Over 900 Points; Comtech Telecommunications Shares Plummet,2020-03-05 14:40:00-05:00,CANF,positive
211146.0,70 Stocks Moving In Thursday's Mid-Day Session,2020-03-05 12:25:00-05:00,CANF,neutral
211147.0,Mid-Day Market Update: WideOpenWest Falls After Q4 Results; Co-Diagnostics Shares Surge,2020-03-05 11:54:00-05:00,CANF,positive
211148.0,"Benzinga Pro's Top 5 Stocks To Watch For Thurs., Mar. 5, 2020: ZM, MRVL, LUV, CODX, CANF",2020-03-05 08:08:00-05:00,CANF,positive
211149.0,"The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19",2020-03-05 08:05:00-05:00,CANF,negative
211150.0,"Can-Fite Highlights Has US Patent Protecting Anti-Viral Effects Of 2 Drug Candidates, Is Exploring Collaboration To Test Candidates Against Coronavirus",2020-03-05 07:05:00-05:00,CANF,neutral
211151.0,Can-Fite Sees Data From Interim Analysis Of Piclidenosen In Phase III Trial Expected Q4'20,2020-03-05 07:04:00-05:00,CANF,neutral
211152.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,CANF,positive
211153.0,"Can-Fite, Univo Say Preclinical Data Results Show CBD's Anti-Cancer Effect In Human Liver Cells",2020-02-27 15:49:00-05:00,CANF,neutral
211154.0,Pre-clinical Studies Demonstrate CBD's Robust Anti-Cancer Effect Against Liver Cancer; Can-Fite and Univo Pharmaceuticals Expand Collaboration Agreement,2020-02-27 06:04:00-05:00,CANF,positive
211155.0,Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications,2020-02-24 07:12:00-05:00,CANF,negative
211156.0,Can-Fite Granted Patent Allowance For Its NASH Drug Namodenoson In South Korea; Co. Notes Results Of Its NASH Phase II Study Are Expected This Quarter,2020-02-18 07:15:00-05:00,CANF,positive
211157.0,80 Biggest Movers From Yesterday,2020-02-11 04:44:00-05:00,CANF,neutral
211158.0,Can-Fite BioPharma Prices ~3.33M Unit Offering At $1.50/Unit,2020-02-10 14:50:00-05:00,CANF,neutral
211159.0,UPDATE: CanFite Shares Halted With Code News Pending,2020-02-10 14:37:00-05:00,CANF,positive
211160.0,CanFite Shares Halted,2020-02-10 14:37:00-05:00,CANF,positive
211161.0,Can-Fite Completes 50% Patient Enrollment In Phase III Rheumatoid Arthritis Study & Implements Interim Analysis,2020-02-03 07:32:00-05:00,CANF,neutral
211162.0,71 Biggest Movers From Yesterday,2020-01-28 04:14:00-05:00,CANF,neutral
211163.0,Mid-Afternoon Market Update: Crude Oil Down 2%; NeuroMetrix Shares Plummet,2020-01-27 14:15:00-05:00,CANF,negative
211164.0,40 Stocks Moving In Monday's Mid-Day Session,2020-01-27 11:59:00-05:00,CANF,neutral
211165.0,30 Stocks Moving in Tuesday's Pre-Market Session,2020-01-21 07:30:00-05:00,CANF,neutral
211166.0,"Can-Fite, Univo Pharma Report Collaboration For Discovery, Applied Patent For Cannabinoid Formulations With Broad Therapeutic Effects",2020-01-16 07:00:00-05:00,CANF,neutral
211167.0,64 Biggest Movers From Yesterday,2020-01-10 04:58:00-05:00,CANF,neutral
211168.0,Mid-Afternoon Market Update: Bed Bath & Beyond Tumbles Following Q3 Miss; Applied Genetic Technologies Shares Jump,2020-01-09 15:11:00-05:00,CANF,positive
211169.0,Mid-Day Market Update: Dow Surges Over 200 Points; Tufin Software Technologies Shares Plunge,2020-01-09 12:14:00-05:00,CANF,positive
211170.0,32 Stocks Moving In Thursday's Mid-Day Session,2020-01-09 12:08:00-05:00,CANF,neutral
211171.0,Can-Fite Announces Exercise Of Warrants For Cash Proceeds Of $2.4M,2020-01-09 09:13:00-05:00,CANF,neutral
211172.0,Can-Fite BioPharma Expects Topline Results from its NASH Phase 2 Study in Q1,2020-01-06 07:09:00-05:00,CANF,neutral
211173.0,53 Biggest Movers From Friday,2020-01-06 05:30:00-05:00,CANF,neutral
211174.0,30 Stocks Moving In Friday's Mid-Day Session,2020-01-03 12:29:00-05:00,CANF,neutral
211175.0,"Can-Fite Reports Pre-Clinical Data Generated At Hadassah Medical Center Showing Namodenoson Induces Weight Loss In Experimental Models, Normalizes Glucose Levels",2020-01-03 07:02:00-05:00,CANF,negative
211176.0,55 Biggest Movers From Yesterday,2019-12-31 04:21:00-05:00,CANF,neutral
211177.0,CEO Of Univo Pharmaceuticals Appointed Board Member At Can-Fite,2019-12-30 09:17:00-05:00,CANF,neutral
211178.0,58 Biggest Movers From Friday,2019-12-30 04:51:00-05:00,CANF,neutral
211179.0,46 Stocks Moving In Friday's Mid-Day Session,2019-12-27 12:05:00-05:00,CANF,neutral
211180.0,60 Biggest Movers From Yesterday,2019-12-27 04:44:00-05:00,CANF,neutral
211181.0,"Mid-Afternoon Market Update: Nasdaq Hits 9,000; Spring Bank Pharmaceuticals Shares Slide",2019-12-26 14:12:00-05:00,CANF,positive
211182.0,34 Stocks Moving In Thursday's Mid-Day Session,2019-12-26 12:11:00-05:00,CANF,neutral
211183.0,Mid-Day Market Update: Crude Oil Up 1%; Spectrum Pharmaceuticals Shares Plunge,2019-12-26 12:00:00-05:00,CANF,negative
211184.0,Can-Fite Reports Strategic Partnership With Univo To Develop Cannabinoid-Based Products Is Ongoing,2019-12-26 07:03:00-05:00,CANF,neutral
211185.0,Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial,2019-12-09 08:19:00-05:00,CANF,neutral
211186.0,75 Biggest Movers From Yesterday,2019-12-06 05:36:00-05:00,CANF,neutral
211187.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-12-05 12:07:00-05:00,CANF,neutral
211188.0,72 Biggest Movers From Yesterday,2019-12-05 05:10:00-05:00,CANF,neutral
211189.0,38 Stocks Moving In Wednesday's Mid-Day Session,2019-12-04 12:02:00-05:00,CANF,neutral
211190.0,75 Biggest Movers From Yesterday,2019-12-03 05:48:00-05:00,CANF,neutral
211191.0,44 Stocks Moving In Monday's Mid-Day Session,2019-12-02 12:11:00-05:00,CANF,neutral
211192.0,18 Stocks Moving in Monday's Pre-Market Session,2019-12-02 07:17:00-05:00,CANF,neutral
211193.0,52 Biggest Movers From Friday,2019-12-02 04:44:00-05:00,CANF,neutral
211194.0,"The Week In Cannabis: FDA Sends Warning Letter, DEA Issues Plan For Cultivation, Kevin Durant Joins Board",2019-12-01 10:11:00-05:00,CANF,negative
211195.0,Mid-Day Market Update: Crude Oil Down 4%; SORL Auto Parts Shares Spike Higher,2019-11-29 12:03:00-05:00,CANF,negative
211196.0,35 Stocks Moving In Friday's Mid-Day Session,2019-11-29 11:40:00-05:00,CANF,neutral
211197.0,Mid-Morning Market Update: Markets Open Lower; Tech Data Shares Climb After $6B Takeover Bid From Apollo,2019-11-29 10:20:00-05:00,CANF,neutral
211198.0,"Benzinga Pro's Top 3 Stocks To Watch For Fri., Nov. 29, 2019: CANF, PCG, BBY",2019-11-29 08:20:00-05:00,CANF,positive
211199.0,"Can Fite Biofarma shares are trading higher following Q3 clinical update, highlighting an agreement with the FDA on its liver cancer study design, a South Korean distribution deal and an agreement to develop cannabinoid-based pharmaceuticals and assays.",2019-11-29 07:53:00-05:00,CANF,positive
211200.0,24 Stocks Moving in Friday's Pre-Market Session,2019-11-29 07:39:00-05:00,CANF,neutral
211201.0,Can-Fite Announces Reached Agreement With FDA On Phase III Liver Cancer Study Design During Q3,2019-11-29 07:23:00-05:00,CANF,negative
211202.0,"Shares of cannabis companies are trading higher, rebounding from recent weakness following large sell offs. NOTE: The sector has been heavily volatile in recent weeks.",2019-11-19 10:37:00-05:00,CANF,negative
211203.0,"Can Fite Biofarma Granted Patents In Canada, South Korea And Israel For Its Sexual Dysfunction Drug",2019-11-19 07:04:00-05:00,CANF,negative
211204.0,Shares of several cannabis companies are trading lower in sympathy with Aurora Cannabis after the company announced last week that it would cancel/delay plans for multiple facility expansions and converted some debt into shares in order to conserve cash.,2019-11-18 11:48:00-05:00,CANF,positive
211205.0,"The Week In Cannabis: Stocks Fall On Poor Earnings, More Americans Support Legalization",2019-11-15 17:12:00-05:00,CANF,neutral
211206.0,Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammals,2019-11-11 09:51:00-05:00,CANF,neutral
211207.0,20 Stocks Moving in Monday's Pre-Market Session,2019-11-11 07:40:00-05:00,CANF,neutral
211208.0,Can-Fite Granted US Patent for Piclidenoson in the Treatment of Osteoarthritis,2019-11-11 07:01:00-05:00,CANF,positive
211209.0,21 Stocks Moving In Monday's Pre-Market Session,2019-11-04 07:56:00-05:00,CANF,neutral
211210.0,"Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients",2019-11-04 07:34:00-05:00,CANF,negative
211211.0,26 Stocks Moving in Friday's Pre-Market Session,2019-11-01 08:03:00-04:00,CANF,neutral
211212.0,23 Biggest Movers From Yesterday,2019-11-01 07:30:00-04:00,CANF,neutral
211213.0,"Mid-Afternoon Market Update: US Markets Down, Dow Loses More Than 200 Points",2019-10-31 14:57:00-04:00,CANF,negative
211214.0,27 Stocks Moving In Thursday's Mid-Day Session,2019-10-31 11:51:00-04:00,CANF,neutral
211215.0,Mid-Day Market Update: Markets Dip After Morning Rise; Oil Plunges,2019-10-31 11:35:00-04:00,CANF,neutral
211216.0,Mid-Morning Market Update: Markets Inch Up; Bristol-Myers Squibb Reports Q3 Beat,2019-10-31 09:56:00-04:00,CANF,neutral
211217.0,Can-Fite Shares Rise 45% Premarket on Announcement FDA Agreed with Co's Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer,2019-10-31 07:37:00-04:00,CANF,positive
211218.0,38 Biggest Movers From Yesterday,2019-10-22 06:42:00-04:00,CANF,neutral
211219.0,33 Stocks Moving In Monday's Mid-Day Session,2019-10-21 12:32:00-04:00,CANF,neutral
211220.0,26 Stocks Moving in Monday's Pre-Market Session,2019-10-21 07:41:00-04:00,CANF,neutral
211221.0,38 Stocks Moving In Friday's Mid-Day Session,2019-10-18 12:30:00-04:00,CANF,neutral
211222.0,48 Biggest Movers From Yesterday,2019-10-18 06:55:00-04:00,CANF,neutral
211223.0,32 Stocks Moving In Thursday's Mid-Day Session,2019-10-17 11:52:00-04:00,CANF,neutral
211224.0,25 Stocks Moving in Tuesday's Pre-Market Session,2019-10-15 07:44:00-04:00,CANF,neutral
211225.0,Can-Fite Completes Patient Enrollment In Phase II NASH Study Of Namodenoson,2019-10-15 06:30:00-04:00,CANF,neutral
211226.0,Can Fite Highlights Publication Of Namodenoson NASH Mechanism Of Action In International Journal of Molecular Medicine,2019-10-10 07:07:00-04:00,CANF,neutral
211227.0,23 Stocks Moving in Wednesday's Pre-Market Session,2019-10-02 07:57:00-04:00,CANF,neutral
211228.0,"H.C. Wainwright Maintains Buy on Can Fite Biofarma, Lowers Price Target to $3",2019-09-24 06:01:00-04:00,CANF,negative
211229.0,"The Week In Cannabis: Big Pharma Makes Moves, Diddy & Wahlberg Go After CBD, Medicine Man Continues M&A Spree",2019-09-13 16:54:00-04:00,CANF,neutral
211230.0,71 Biggest Movers From Yesterday,2019-09-12 05:33:00-04:00,CANF,neutral
211231.0,UPDATE: Capital Point Filing On Can-Fite Shows Firm Filed Request For Temporary Injunction With Tel Aviv-Yafo District Court To Prevent Execution Of Collaboration Deal Between Co. Univo Pharma,2019-09-11 16:43:00-04:00,CANF,neutral
211232.0,"Can-Fite BioPharma Amended 13D Filing From Capital Point Shows 12.88% Stake, Includes Language Firm Initiated Added Legal Proceedings In Tel Aviv-Yafo District Court To Compel Co. To Convene Special General Meeting Of Shareholders",2019-09-11 16:42:00-04:00,CANF,positive
211233.0,48 Stocks Moving In Wednesday's Mid-Day Session,2019-09-11 12:27:00-04:00,CANF,neutral
211234.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday., September 11, 2019",2019-09-11 09:24:00-04:00,CANF,positive
211235.0,26 Stocks Moving in Wednesday's Pre-Market Session,2019-09-11 07:59:00-04:00,CANF,neutral
211236.0,80 Biggest Movers From Yesterday,2019-09-11 05:11:00-04:00,CANF,neutral
211237.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-09-10 12:19:00-04:00,CANF,neutral
211238.0,"Can-Fite Partners, Univo Pharmaceuticals Join Forces On Medical Cannabis-Based Therapeutics",2019-09-10 10:58:00-04:00,CANF,positive
211239.0,Mid-Morning Market Update: Markets Open Lower; HD Supply Posts Mixed Q2 Results,2019-09-10 10:24:00-04:00,CANF,negative
211240.0,28 Stocks Moving in Tuesday's Pre-Market Session,2019-09-10 07:51:00-04:00,CANF,neutral
211241.0,Can-Fite shares are trading higher after the company entered into an agreement with Univo Pharmaceuticals to develop cannabinoid-based pharmaceuticals and assays.,2019-09-10 06:44:00-04:00,CANF,positive
211242.0,Can-Fite Enters Into Agreement With Univo Pharmaceuticals To Develop Cannabinoid-Based Pharmaceuticals And Assays,2019-09-10 06:05:00-04:00,CANF,positive
211243.0,Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays,2019-09-10 06:03:00-04:00,CANF,positive
211244.0,Can-Fite Reports Top-Line Data From Phase II Nash Study With Namodenoson Expected Q4 2019,2019-08-29 07:14:00-04:00,CANF,neutral
211245.0,Can-Fite Reports Preparatory Work For An End Of Phase II Meeting With FDA To Initiate Phase III Study In Liver Cancer Is Ongoing; Patient Enrollment Continues In Two Phase III Studies For Piclidenoson In The Treatment Of Rheumatoid Arthritis And Psoriasis,2019-08-29 07:13:00-04:00,CANF,negative
211246.0,10 Biopharmaceutical Companies Trying To Cure Cancer,2019-08-24 13:46:00-04:00,CANF,negative
211247.0,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study",2019-08-22 07:18:00-04:00,CANF,positive
211248.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,CANF,neutral
211249.0,Can Fite Biofarma shares are trading higher after the company announced that a supply of Namodenoson has been manufactured and is ready for use in the treatment of advanced liver cancer patients.,2019-08-06 08:36:00-04:00,CANF,positive
211250.0,Can-Fite BioPharma Announces That A Supply Of Namodenoson Has Been Manufactured And Is Ready For Use In The Treatment Of Advanced Liver Cancer Patients,2019-08-06 07:16:00-04:00,CANF,negative
211251.0,"Can-Fite BioPharma 6-K Shows Co. Received Letter From Capital Point On Aug. 1, 2019 Requesting Co. Convene Shareholders Meeting To Amend Articles Of Association, Replace Board Members, Dismiss CEO",2019-08-05 16:56:00-04:00,CANF,neutral
211252.0,Can-Fite BioPharma Reports $4M Deal With Kyongbo Pharm,2019-08-01 09:38:00-04:00,CANF,neutral
211253.0,"Can-Fite BioPharma Reports Deal With Kyongbo Pharm For Distribution In South Korea Of Piclidenoson For Psoriasis, Will Receive $4M Upfront, Milestone Payments",2019-08-01 08:47:00-04:00,CANF,neutral
211254.0,Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm,2019-07-10 09:56:00-04:00,CANF,negative
211255.0,"UPDATE: Can-Fite Says Supreme Court Granted Motion On Temporary Basis Pending Any Other Decision, Co. Says Will Vigorously Defend Itself",2019-07-09 16:38:00-04:00,CANF,positive
211256.0,UPDATE: Can-Fite Says Supreme Court Appeal Filed Motion To Stay Execution Of District Court Pending Decision On Appeal,2019-07-09 16:37:00-04:00,CANF,positive
211257.0,Can-Fite BioPharma 6-K Shows Co. Filed Appeal With Supreme Court Appealing Decision Related To Convening Of Special Shareholders Meeting To Replace Directors,2019-07-09 16:36:00-04:00,CANF,positive
211258.0,36 Stocks Moving In Thursday's Pre-Market Session,2019-06-27 08:12:00-04:00,CANF,neutral
211259.0,30 Stocks Moving In Tuesday's Pre-Market Session,2019-06-25 08:04:00-04:00,CANF,neutral
211260.0,"Can-Fite BioPharma Files Lawsuit AGainst Capital Point Alleging 'improper conduct in its attempt to exert control over the Company by, among things, unlawfully requesting that the Company convene a shareholders' meeting to replace its directors.'",2019-06-18 16:58:00-04:00,CANF,negative
211261.0,30 Stocks Moving In Thursday's Pre-Market Session,2019-06-06 08:24:00-04:00,CANF,neutral
211262.0,30 Stocks Moving In Monday's Pre-Market Session,2019-06-03 08:12:00-04:00,CANF,neutral
211263.0,Can-Fite's Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session,2019-06-03 07:15:00-04:00,CANF,negative
211264.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,CANF,neutral
211265.0,56 Biggest Movers From Yesterday,2019-05-31 06:14:00-04:00,CANF,neutral
211266.0,"The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug",2019-05-30 07:33:00-04:00,CANF,positive
211267.0,"Can-Fite Biopharma Q1 EPS $(0.04) Misses $(0.01) Estimate, Sales $299K Down From $632K YoY",2019-05-29 07:02:00-04:00,CANF,negative
211268.0,Secondary Offerings Put A Pause On May's Momentum,2019-05-24 13:46:00-04:00,CANF,neutral
211269.0,Can-Fite Biopharma 8-K Shows Co. Received Letter On Behalf Of Capital Point Stating Firm Acquired Shares Of Co. Representing 5+% Of Outstanding Shares,2019-05-24 09:11:00-04:00,CANF,positive
211270.0,55 Biggest Movers From Yesterday,2019-05-23 04:56:00-04:00,CANF,neutral
211271.0,Can-Fite 13G Filing From Sabby Mgmt. Shows New 9.79% Stake,2019-05-22 14:40:00-04:00,CANF,neutral
211272.0,41 Stocks Moving In Wednesday's Mid-Day Session,2019-05-22 12:32:00-04:00,CANF,neutral
211273.0,"A Look At Benzinga Pro's 10 Most-Searched Tickers For May 21, 2019",2019-05-21 13:05:00-04:00,CANF,neutral
211274.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., May 21, 2019",2019-05-21 09:23:00-04:00,CANF,positive
211275.0,52 Biggest Movers From Yesterday,2019-05-21 05:05:00-04:00,CANF,neutral
211276.0,"A Look At Benzinga Pro's 10 Most-Searched Tickers For May 20, 2019",2019-05-20 15:50:00-04:00,CANF,neutral
211277.0,"Can-Fite Shares Resume Trade, Continue Lower; Down 35% For Session",2019-05-20 15:01:00-04:00,CANF,neutral
211278.0,"Can-Fite Shares Resume Trade, Halted On Second Circuit Breaker; Shares Down 30% For Session",2019-05-20 14:56:00-04:00,CANF,positive
211279.0,Mid-Afternoon Market Update: Dow Falls Over 100 Points; Sprint Shares Spike Higher,2019-05-20 14:42:00-04:00,CANF,positive
211280.0,"Can-Fite Shares Resume Trade, Move Lower, Halted On Circuit Breaker, Up 13.6% For Session",2019-05-20 14:25:00-04:00,CANF,neutral
211281.0,Can-Fite Reports $6M Registered Direct Offering,2019-05-20 14:08:00-04:00,CANF,neutral
211282.0,Can-Fite Shares Halted News Pending,2019-05-20 13:59:00-04:00,CANF,positive
211283.0,36 Stocks Moving In Monday's Mid-Day Session,2019-05-20 12:32:00-04:00,CANF,neutral
211284.0,Mid-Day Market Update: Pinduoduo Falls After Q1 Results; Biocept Shares Jump,2019-05-20 12:15:00-04:00,CANF,positive
211285.0,Can-Fite Abstract Selected For Liver Conference,2019-05-20 11:52:00-04:00,CANF,neutral
211286.0,Mid-Morning Market Update: Markets Open Lower; International Game Technology Earnings Miss Views,2019-05-20 10:12:00-04:00,CANF,negative
211287.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Mon., May 20, 2019",2019-05-20 10:12:00-04:00,CANF,positive
211288.0,Can-Fite Biopharma shares are trading lower after the company announced a $6 million registered direct offering.,2019-05-20 09:49:00-04:00,CANF,neutral
211289.0,Can-Fite Reports Its Phase II Liver Cancer Data Selected For Presentation At International Liver Cancer Association,2019-05-20 07:06:00-04:00,CANF,negative
211290.0,Can-Fite BioPharma Highlights Is Conducting Preparatory Work For Planned Pivotal Phase III Study Of Namodenoson In Treatment Of Advanced Live Cancer,2019-05-06 07:10:00-04:00,CANF,negative
211291.0,Can-Fite Biopharma Recieves a $1M Payment From CKD for Distribution of Namodenoson in South Korea,2019-04-15 07:14:00-04:00,CANF,neutral
211292.0,Can-Fite BioPharma 13G From Intracoastal Capital Shows New 9.99% Stake,2019-04-12 06:31:00-04:00,CANF,neutral
211293.0,Can-Fite BioPharma shares are trading lower after the company reported a $3.2 million registered direct offering.,2019-04-02 09:26:00-04:00,CANF,neutral
211294.0,Can-Fite BioPharma Reports $3.2M Registered Direct Offering,2019-04-02 09:02:00-04:00,CANF,neutral
211295.0,58 Biggest Movers From Yesterday,2019-03-27 04:22:00-04:00,CANF,neutral
211296.0,Mid-Afternoon Market Update: Ameri Holdings Drops After FY18 Results; Bed Bath & Beyond Shares Jump,2019-03-26 15:00:00-04:00,CANF,positive
211297.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-03-26 13:20:00-04:00,CANF,neutral
211298.0,Mid-Day Market Update: Crude Oil Up Over 2%; Aldeyra Therapeutics Shares Spike Higher,2019-03-26 12:22:00-04:00,CANF,negative
211299.0,Mid-Morning Market Update: Markets Open Higher; Carnival Issues Weak Profit Outlook,2019-03-26 10:09:00-04:00,CANF,neutral
211300.0,28 Stocks Moving In Tuesday's Pre-Market Session,2019-03-26 08:39:00-04:00,CANF,neutral
211301.0,Can-Fite shares are trading lower after the company's phase 2 trial for advanced liver cancer did not meet its primary endpoint.,2019-03-26 07:45:00-04:00,CANF,negative
211302.0,"Can-Fite Reports Results For Phase II Advanced Liver Cancer Trial , Namodenoson: Did Not Met Primary Endpoint",2019-03-26 07:02:00-04:00,CANF,negative
211303.0,Can-Fite BioPharma Filing Shows Registration For ~2.35M ADS Offering Via Selling Shareholders,2019-03-12 17:02:00-04:00,CANF,neutral
211304.0,"Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication, Can-Fite to Receive $1M Upfront",2019-02-25 07:08:00-05:00,CANF,positive
211305.0,Can-Fite Granted a Patent by the USPTO For its A3 Adenosine Receptor in the Treatment of Osteoarthritis,2019-02-04 07:02:00-05:00,CANF,positive
211306.0,Can-Fite Issues Press Release Highlighting 'drugs robustly inhibit the release of inflammatory mediators that induce Cytokine Release Syndrome',2019-01-30 07:10:00-05:00,CANF,negative
211307.0,Can-Fite BioPharma's CEO Issues a Letter to Shareholders,2019-01-24 07:31:00-05:00,CANF,neutral
211308.0,"Can-Fite CEO Sends Letter To Shareholders, Highlights Near-Term Milestones",2019-01-24 07:30:00-05:00,CANF,neutral
211309.0,Can-Fite BioPharma Announces a 2.24M share registered direct offering at $1.05/share.,2019-01-18 08:02:00-05:00,CANF,positive
211310.0,Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson's Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC,2018-12-10 07:06:00-05:00,CANF,positive
211311.0,"Can-Fite Reports Results For 9 Months Ended Sep. 30, 2018: EPS $(0.08) vs $(0.14) In Same Period Last Year, Sales $3.531M vs $704K Year Over Year",2018-11-30 07:03:00-05:00,CANF,neutral
211312.0,Can-Fite Shares Spike ~15% On Uptick In Volume; Not Yet Seeing Fundamental Reason To Justify Move Higher,2018-11-21 13:14:00-05:00,CANF,positive
211313.0,"Can-Fite Biopharma Says Due To Patient Survival, Top Line Efficacy Results Of Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19",2018-10-31 07:48:00-04:00,CANF,negative
211314.0,26 Stocks Moving In Friday's Pre-Market Session,2018-08-31 08:08:00-04:00,CANF,neutral
211315.0,"Can-Fite 1H'18 EPS $(0.08) vs $(0.10) In Same Period Last Year, Sales $902K vs $136K Year Over Year",2018-08-31 07:02:00-04:00,CANF,neutral
211316.0,Can-Fite BioPharma Reports Enrollment Of First Patient In Comfort Phase III Trial Of Piclidenoson In Psoriasis,2018-08-21 07:30:00-04:00,CANF,positive
211317.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Mon., Jul. 6, 2018",2018-08-06 12:04:00-04:00,CANF,positive
211318.0,"Can-Fite Announces Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical; Can-Fite to $2M Upfront; Up to $74.5M in Milestones, Royalties",2018-08-06 06:26:00-04:00,CANF,positive
211319.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-17 08:56:00-04:00,CANF,neutral
211320.0,Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug,2018-07-17 07:01:00-04:00,CANF,negative
211321.0,38 Stocks Moving In Monday's Mid-Day Session,2018-07-02 12:29:00-04:00,CANF,neutral
211322.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-02 09:10:00-04:00,CANF,neutral
211323.0,28 Stocks Moving In Monday's Pre-Market Session,2018-07-02 08:06:00-04:00,CANF,neutral
211324.0,Can-Fite BioPharma Shares are Trading Higher After Announces the Publication of a Paper Recommending Development of Anti-Liver Cancer Drugs Based on Namodenoson,2018-07-02 07:19:00-04:00,CANF,negative
211325.0,Can Fite Biofarma Shares Up 6.7% After Co. Gave Update On Phase II Trial Of Namodenoson For Advanced Liver Cancer; Co. Said Accumulated Safety Data Indicates 'Favorable' Drug Safety Profile,2018-06-19 13:35:00-04:00,CANF,positive
211326.0,"Can-Fite BioPharma Offers Update On Status Of Phase II Advanced Liver Cancer Trial: Of 78 Patients Originally Enrolled, 19 Completed At Least 12 Cycles Of Treatment, 3 Completed At Least 24 Cycles",2018-06-19 07:07:00-04:00,CANF,negative
211327.0,Can-Fite Says Accumulated Safety Data Continues To Indicate A Favorable Drug Safety Profile,2018-06-19 07:02:00-04:00,CANF,positive
211328.0,Maxim Group Terminates Can-Fite Biopharma Ltd Coverage,2018-06-15 16:30:00-04:00,CANF,neutral
211329.0,31 Stocks Moving In Wednesday's Mid-Day Session,2018-06-13 12:22:00-04:00,CANF,neutral
211330.0,"Benzinga's Top Upgrades, Downgrades For June 13, 2018",2018-06-13 09:19:00-04:00,CANF,positive
211331.0,Benzinga Pro's 5 Stocks To Watch Today,2018-06-13 08:55:00-04:00,CANF,neutral
211332.0,"H.C. Wainwright Assumes Can-Fite Biopharma Ltd Sponsored ADR (Israel) at Buy, Announces Price Target $8",2018-06-13 07:21:00-04:00,CANF,neutral
211333.0,Benzinga Pro's 5 Stocks To Watch Today,2018-06-11 09:32:00-04:00,CANF,neutral
211334.0,"Can-Fite Reports On New Pre-Clinical Developments With Its NASH Drug Namodenoson; Co. Reports Robust Anti-NASH Effects When Drug Administered Orally, Says Data Supports Selection Of Primary Endpoint For Phase 2 Study",2018-06-11 07:05:00-04:00,CANF,positive
211335.0,40 Biggest Movers From Friday,2018-06-04 04:33:00-04:00,CANF,neutral
211336.0,26 Stocks Moving In Friday's Mid-Day Session,2018-06-01 11:55:00-04:00,CANF,neutral
211337.0,26 Stocks Moving In Friday's Pre-Market Session,2018-06-01 08:03:00-04:00,CANF,neutral
211338.0,"Can-Fite Biopharma Ltd Sponsored ADR (Israel) Q1 EPS $(0.05) Beats $(0.06) Estimate, Sales $632K Beat $140K Estimate",2018-06-01 07:04:00-04:00,CANF,neutral
211339.0,"Can-Fite Reports FY17 Net Loss $1.89M vs $1.82M In FY16, Sales $850K vs $200K In FY16",2018-03-23 07:06:00-04:00,CANF,negative
211340.0,Sabby Management Reports 8.34% Stake In Can-Fite Biopharma,2018-03-13 14:52:00-04:00,CANF,neutral
211341.0,Maxim Group Downgrades Can-Fite Biopharma Ltd Sponsored ADR (Israel) to Hold,2018-03-09 12:54:00-05:00,CANF,neutral
211342.0,Can Fite Anticipates Phase II NASH Study Data Release To Occur In First Half Of 2019,2018-02-28 09:26:00-05:00,CANF,neutral
211343.0,Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson,2018-02-12 07:07:00-05:00,CANF,positive
211344.0,28 Stocks Moving In Monday's Pre-Market Session,2018-02-05 08:07:00-05:00,CANF,neutral
211345.0,"Can-Fite Shares Down ~$0.05-$0.10 Over Last Min., Down 3.2% For Session As Traders Circulating Street Sweeper Alert From Monday; Watch For Rebound From Low",2018-01-31 11:28:00-05:00,CANF,positive
211346.0,StreetSweeper Issues Short Report On Can-Fite Biopharma,2018-01-29 13:38:00-05:00,CANF,neutral
211347.0,"Can-Fite Receives its First Payment of $2.2M From Gebro For the Distribution of Piclidenoson, Up to $7M of Additional Milestone Payments Eligible",2018-01-25 07:10:00-05:00,CANF,neutral
211348.0,"Can-Fite Says It Expects 2 Phase II Studies In Rehumatoid Arthritis And Psoriasis In 12 Months, Along With A Data Release From Phase II Liver Cancer Trial And A Complete Enrollment For The NASH Study",2018-01-11 07:04:00-05:00,CANF,negative
211349.0,Can-Fite BioPharma Reports Signing Of Up To $9M Distribution Deal With Gebro Holdings For Piclidenoson In 3 European Countries,2018-01-08 07:44:00-05:00,CANF,neutral
211350.0,"Can-Fite Announces a Collaborative Research Agreement with Hadassah Medical Center, A Phase 2 Study of Namodenoson to Enroll NAFLD/NASH Patients",2018-01-03 07:04:00-05:00,CANF,positive
211351.0,40 Biggest Movers From Yesterday,2017-12-19 05:15:00-05:00,CANF,neutral
211352.0,34 Stocks Moving In Monday's Mid-Day Session,2017-12-18 12:28:00-05:00,CANF,neutral
211353.0,31 Stocks Moving In Monday's Pre-Market Session,2017-12-18 08:12:00-05:00,CANF,neutral
211354.0,Can-Fite Gives an Updated on its Phase 2 Liver Cancer Trial,2017-12-18 07:12:00-05:00,CANF,negative
211355.0,"Can-Fite Reports Q3 EPS $(0.12) vs $(0.08) Est., Sales $740K vs $40K Est.",2017-11-27 07:31:00-05:00,CANF,neutral
211356.0,Can-Fite Enrolls the First Patient in Phase II NAFLD/NASH Study with Namodenoson,2017-11-27 07:07:00-05:00,CANF,neutral
211357.0,Can-Fite Reports Enrollment Of First Patient In ACRobat Phase III Trial Of Piclidenoson In RA,2017-10-30 09:50:00-04:00,CANF,neutral
211358.0,F-3 From Can-Fite BioPharma Shows Registration For $50M Mixed Securities Shelf Offering,2017-09-26 16:36:00-04:00,CANF,positive
211359.0,"Can-Fite 6 Month EPS $(0.10), Sales $152K vs $60K Est.",2017-09-01 07:01:00-04:00,CANF,neutral
211360.0,Can-Fite Recieves $500K Milestone Payment from Chong Kun Dang Pharma,2017-08-23 07:01:00-04:00,CANF,neutral
211361.0,18 Biggest Mid-Day Gainers For Friday,2017-08-11 12:17:00-04:00,CANF,neutral
211362.0,"Benzinga's Top Upgrades, Downgrades For August 11, 2017",2017-08-11 09:28:00-04:00,CANF,positive
211363.0,"Maxim Group Initiates Coverage On Can-Fite Biopharma Ltd Sponsored ADR (Israel) with Buy Rating, Announces $7.00 Price Target",2017-08-11 08:25:00-04:00,CANF,neutral
211364.0,Can-Fite BioPharma Cleared to Initiate 2 Phase III Studies for Piclidenoson following Completion of Cardiodynamic Trial,2017-08-07 07:09:00-04:00,CANF,positive
211365.0,Can-Fite Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of RA,2017-06-08 07:19:00-04:00,CANF,positive
211366.0,Can-Fite BioPharma Files for 1.375M ADS Offering,2017-05-30 13:43:00-04:00,CANF,neutral
211367.0,Monday's Market In 5 Minutes,2017-05-30 08:31:00-04:00,CANF,neutral
211368.0,"Can-Fite Q1 EPS $0.04 vs $(0.09) Est, Sales $73K",2017-05-30 07:04:00-04:00,CANF,neutral
211369.0,Can-Fite Files Clinical Trail Application with Health Canada for Piclidenoson,2017-05-16 07:13:00-04:00,CANF,neutral
211370.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-04-26 08:22:00-04:00,CANF,neutral
211371.0,20 Biggest Mid-Day Gainers For Tuesday,2017-04-25 12:43:00-04:00,CANF,neutral
211372.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-04-25 08:21:00-04:00,CANF,neutral
211373.0,Can-Fite Reports Phase III ACRobat Trial in RA Approved by Institutional Review Board,2017-04-25 07:15:00-04:00,CANF,positive
211374.0,"Can-Fite Reports FY16 EPS $(0.25) vs. $(0.31) Est., Sales $170K vs. $370K",2017-03-31 07:05:00-04:00,CANF,neutral
211375.0,15 Biggest Mid-Day Gainers For Tuesday,2017-02-28 12:44:00-05:00,CANF,neutral
211376.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-02-28 08:30:00-05:00,CANF,neutral
211377.0,New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis,2017-02-28 07:55:00-05:00,CANF,positive
211378.0,15 Biggest Mid-Day Losers For Thursday,2017-01-19 13:25:00-05:00,CANF,negative
211379.0,20 Stocks Moving In Thursday's Pre-Market Session,2017-01-19 08:19:00-05:00,CANF,neutral
211380.0,Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017,2017-01-09 07:24:00-05:00,CANF,positive
211381.0,Can-Fite Gets $500K Milestone Payment,2016-12-21 07:01:00-05:00,CANF,neutral
211382.0,15 Stocks Moving In Friday's Pre-Market Session,2016-12-16 08:42:00-05:00,CANF,neutral
211383.0,New Preclinical Data Show Can-Fite's Namodenoson  Inhibits Liver Fibrosis,2016-12-16 07:08:00-05:00,CANF,negative
211384.0,The Market In 5 Minutes: Black Friday Closes Shortened Trading Week,2016-11-25 09:33:00-05:00,CANF,neutral
211386.0,Can-Fite BioPharma Reached Agreement with EMA on Final Design of Global Pivotal Phase III Trial for Piclidenoson in Treatment of of Psoriasis,2016-11-01 07:20:00-04:00,CANF,positive
211387.0,"Can-Fite Signs Distribution Deal for Liver Cancer Drug CF102 in South Korea, Will Receive $3M Upfront And Milestone Payments & Percentage Rate Of Royalties In Low Twenties",2016-10-25 07:16:00-04:00,CANF,negative
211388.0,Roth Capital Assumes Can-Fite Biopharma Ltd Sponsored ADR (Israel) at Buy,2016-10-19 08:03:00-04:00,CANF,neutral
211389.0,Can-Fite Submits Protocol for Phase II Trial of CF102 in Treatment of NAFLD/NASH,2016-10-13 07:17:00-04:00,CANF,neutral
211390.0,"Can-Fite Shares Up 10% as Co. Earlier Offered Positive New Data on CF102's Live Protective, Regenerative Properties, Showed Candidate Protects Against Ischemia/Reperfusion Injury, Liver Hepatectomy",2016-09-20 11:04:00-04:00,CANF,positive
211391.0,"Rodman & Renshaw Assumes Can Fite Biofarma at Buy, Announces $6.00 PT",2016-08-29 07:05:00-04:00,CANF,neutral
211392.0,"Can-Fite Reports Six Months Ended Rev. $111K, EPS $0.10",2016-08-26 07:01:00-04:00,CANF,neutral
211393.0,"Can-Fite BioPharma Says Israel Court Approves Application to Extend Term of Series 11 Warrants until October 31, 2016",2016-07-14 07:11:00-04:00,CANF,positive
211394.0,Mid-Afternoon Market Update: Dow Falls 140 Points; Insys Therapeutics Shares Surge Following FDA Approval of Syndros,2016-07-05 14:33:00-04:00,CANF,positive
211395.0,10 Biggest Mid-Day Losers For Tuesday,2016-07-05 13:31:00-04:00,CANF,negative
211396.0,Mid-Day Market Update: Crude Oil Down Over 4%; Himax Technologies Shares Spike Higher,2016-07-05 12:20:00-04:00,CANF,negative
211397.0,Mid-Morning Market Update: Markets Open Lower; Tesla's Deliveries Hit Near 2-Year Low,2016-07-05 10:11:00-04:00,CANF,negative
211398.0,"Can-Fite BioPharma Reports Phase 2 Glaucoma Data Misses Primary Endpoint, No Statistically Significant Difference In CF101 Treated Group vs. Placebo; Sees No Immediate Path Forward In Galucoma",2016-07-05 07:04:00-04:00,CANF,negative
211399.0,"Can-Fite BioPharma Announces Israel Court Grants Extension of Term of Series 11 Warrants Until July 14, 2016",2016-06-27 06:14:00-04:00,CANF,positive
211400.0,UPDATE: Can-Fite BioPharma Reports Psoriasis Drug Piclidenoson Inhibits 2 Inflammatory Cytokines IL-17 and IL-23,2016-06-15 07:11:00-04:00,CANF,negative
211401.0,Can-Fite BioPharma Reports New Data Demonstrating Psoriasis Drug Could Offer Efficacy Similar to Industry-Leading Biologics Without Harmful Side Effects,2016-06-15 07:03:00-04:00,CANF,neutral
211402.0,"Can-Fite Bio Pharma Files Application With Lod District Court in Israel to Approve Extension of Term of Series 11 Warrants until October 31, 2016",2016-06-14 07:27:00-04:00,CANF,neutral
211403.0,"Can-Fite Reports Submission of Psoriasis Phase III Protocol, Registration Plan to EMA for CF101",2016-06-07 07:06:00-04:00,CANF,neutral
211404.0,Can-Fite Announces Agreement Reached with EMA on Phase 3 Trial Design,2016-06-01 07:11:00-04:00,CANF,positive
211405.0,Can-Fite Announces Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis,2016-06-01 07:07:00-04:00,CANF,positive
211406.0,"Can-Fite Reports Q1 EPS $(0.06), Sales $57K",2016-05-27 07:05:00-04:00,CANF,neutral
211407.0,"Can-Fite BioPharma Announces Court Approved Company's Application to Extend Term of Series 11 Warrants until June 30, 2016",2016-04-13 07:18:00-04:00,CANF,positive
211408.0,"Can-Fite BioPharma Announces Positive Results for CF602, Plans to File Investigational New Drug Application",2016-04-11 07:07:00-04:00,CANF,positive
211409.0,"Can-Fite Reports 2015 Financial Results, Provides Clinical Pipeline Update",2016-04-01 08:19:00-04:00,CANF,neutral
211410.0,"Can-Fite Gives Phase 3 Protocol Design, Registration TO EMA For CF101 In Treatment Of Rheumatoid Arthritis",2016-03-17 07:02:00-04:00,CANF,neutral
211411.0,Napodano: CanFite Worth Multiples Of Current Valuation,2016-02-08 10:22:00-05:00,CANF,positive
211412.0,USPTO Issues Notice of Allowance for Can-Fite's Sexual Dysfunction Drug CF602,2016-01-19 07:19:00-05:00,CANF,negative
211413.0,"Can-Fite  Phase III Trials in RA, Psoriasis Expected to Commence in 2016;  Planning Phase II Trial for New indication in NASH",2016-01-11 07:11:00-05:00,CANF,neutral
211414.0,Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis,2016-01-05 07:22:00-05:00,CANF,neutral
211415.0,"Can-Fite Subsidiary OphthaliX, Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101",2015-12-07 07:18:00-05:00,CANF,neutral
211416.0,Can-Fite Biopharma +5% Premarket; H.C. Wainwright Raises PT from $4 to $6; Maintains Buy Rating,2015-11-30 07:19:00-05:00,CANF,neutral
211417.0,Morning Market Gainers,2015-11-27 09:40:00-05:00,CANF,neutral
211418.0,Can-Fite Sahres +17% Following Earnings Report,2015-11-27 07:35:00-05:00,CANF,neutral
211419.0,Can-Fite Reports 9 Month Ended EPS ($0.24),2015-11-27 07:02:00-05:00,CANF,neutral
211420.0,Morning Market Gainers,2015-11-23 09:44:00-05:00,CANF,neutral
211422.0,Can-Fite Reports Supportive Pre-Clinical Data On CF102 For Treatment Of Non-Alcoholic Steatohepatitis,2015-11-23 07:04:00-05:00,CANF,positive
211423.0,Can-Fite Spikes to High,2015-10-28 12:09:00-04:00,CANF,neutral
211424.0,Can-Fite +12.5% Premarket Following Announcement of New Study Demonstrating CF602 Mechanism of Action to Improve Sexual Dysfunction,2015-10-22 07:25:00-04:00,CANF,neutral
211425.0,Can-Fite BioPharma 6K Out on Securities Purchase Agreement,2015-10-15 09:22:00-04:00,CANF,positive
211426.0,"Can-Fite BioPharma Adjourns Today's Scheduled Annual Meeting till Wednesday, October 22, 2015 Due to Lack of Quorum",2015-10-15 08:46:00-04:00,CANF,negative
211427.0,Can-Fite Pharma REports $4.8M Registerd Direct Offering,2015-10-13 08:02:00-04:00,CANF,neutral
211428.0,Morning Market Gainers,2015-10-12 09:43:00-04:00,CANF,neutral
211429.0,Can-Fite BioPharma +9.5% Premarket on Announcement of EMA Orphan Designation for CF102,2015-10-12 07:21:00-04:00,CANF,neutral
211430.0,EMA Grants Orphan Designation to Can-Fite's CF102 in the Treatment of Liver Cancer,2015-10-12 07:06:00-04:00,CANF,negative
211431.0,Can-Fite Biopharma Shares Spiking Higher,2015-10-07 13:28:00-04:00,CANF,positive
211432.0,"Can-Fite to Deliver 2 Presentations on its Cancer Drug CF102 at the 20th World Congress on Advances in Oncology and 18th International Symposium on Molecular Medicine on October 8-10, 2015 in Athens",2015-10-07 07:04:00-04:00,CANF,negative
211433.0,Morning Market Losers,2015-10-01 09:56:00-04:00,CANF,negative
211434.0,"Sabby Healthcare Master Fund, Ltd. Reports 9.57% Stake in Can-Fite BioPharma in 13G Filing",2015-09-26 07:00:00-04:00,CANF,neutral
211435.0,Hearing Unconfirmed Market Chatter of Baker Bros Stake in Canfite,2015-09-25 10:42:00-04:00,CANF,negative
211436.0,Morning Market Losers,2015-09-24 09:52:00-04:00,CANF,negative
211437.0,Morning Market Gainers,2015-09-22 09:57:00-04:00,CANF,neutral
211438.0,Mid-Morning Market Update: Markets Open Higher; Lennar Tops Q3 Views,2015-09-21 10:29:00-04:00,CANF,positive
211439.0,Morning Market Losers,2015-09-21 09:52:00-04:00,CANF,negative
211440.0,Benzinga's Top #PreMarket Losers,2015-09-21 08:21:00-04:00,CANF,negative
211441.0,Can-Fite BioPharma Shares Fall 11% Premarket Following Announcement of $9M Registered Direct Offering,2015-09-21 04:53:00-04:00,CANF,positive
211442.0,Can-Fite BioPharma Announces $9M Registered Direct Offering; ~2.068M ADSs @$4.35/ADS,2015-09-20 10:19:00-04:00,CANF,neutral
211443.0,Can-Fite +108% @$6.85,2015-09-18 12:54:00-04:00,CANF,neutral
211444.0,Morning Market Gainers,2015-09-18 09:44:00-04:00,CANF,neutral
211445.0,Can-Fite +19% Premarket,2015-09-18 07:39:00-04:00,CANF,neutral
211446.0,Morning Market Gainers,2015-09-17 09:42:00-04:00,CANF,neutral
211447.0,Benzinga's Top #PreMarket Gainers,2015-09-17 08:10:00-04:00,CANF,positive
211448.0,UPDATE: Can-Fite +56% at $2.62,2015-09-17 07:37:00-04:00,CANF,neutral
211449.0,Can-Fite +37% Premarket Following Announcement of FDA Fast Track Designation for CF102 in Treatment of Liver Cancer,2015-09-17 07:25:00-04:00,CANF,negative
211450.0,FDA Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer,2015-09-17 07:10:00-04:00,CANF,negative
211451.0,WHO Accepts 'Piclidenoson' as Proposed New Generic Name for Can-Fite's Lead Drug Candidate CF101,2015-07-29 07:10:00-04:00,CANF,positive
211452.0,Can-Fite Shares Move Higher; Mentioned as Play on Inotek,2015-07-23 12:18:00-04:00,CANF,positive
211453.0,"Can-Fite Announces it Will Join Israeli Life Sciences Delegation to Japan on July 28 - 30, 2015",2015-07-23 07:08:00-04:00,CANF,positive
211454.0,US Stock Futures Signal Lower Start On Wall Street,2015-06-29 07:28:00-04:00,CANF,negative
211455.0,Can-Fite's CF602 Sexual Dysfunction Drug Backed by New Preclinical Data Progresses Towards an IND,2015-06-29 07:01:00-04:00,CANF,negative
211456.0,Can-Fite Subsidiary OphthaliX to Acquire Improved Vision Systems,2015-06-19 07:04:00-04:00,CANF,positive
211457.0,"Can-Fite to Exhibit at Bio International Convention in Philadelphia on June 15 - 18, 2015",2015-06-15 07:05:00-04:00,CANF,neutral
211458.0,Can-Fite Granted Notice of Allowance for Patent Covering Manufacturing Process of CF101 in the U.S.,2015-06-10 08:23:00-04:00,CANF,positive
211459.0,Can-Fite's Phase 2 Trial Approved In Europe,2015-05-11 07:05:00-04:00,CANF,positive
211460.0,Can-Fite Announces Phase II Liver Cancer Trial Approved in Europe,2015-05-11 07:03:00-04:00,CANF,negative
211461.0,"Can-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd.",2015-05-04 08:53:00-04:00,CANF,positive
211462.0,Morning Market Gainers,2015-04-27 09:43:00-04:00,CANF,neutral
211463.0,Benzinga's Top #PreMarket Gainers,2015-04-27 08:05:00-04:00,CANF,positive
211464.0,UPDATE: Can-Fite Shares Rise 38% Premarket on Positive Results from Further Analysis of Phase II/III Psoriasis Trial,2015-04-27 07:22:00-04:00,CANF,positive
211465.0,Can-Fite Applies for Orphan Drug Designation in Europe for CF102 for Treatment of Liver Cancer,2015-04-20 07:04:00-04:00,CANF,negative
211466.0,Morning Market Losers,2015-03-30 09:49:00-04:00,CANF,negative
211467.0,Shares of Can-Fite Plummet from ~$5.80 on Friday to $2.80 in Pre-Market Action Following News Top-Line Results from Phase II/III Trial for CF101 Did Not Hit Primary Efficacy Endpoint,2015-03-30 09:19:00-04:00,CANF,positive
211468.0,US Stock Futures Edge Lower Ahead Of Existing-Home Sales Data,2015-03-23 07:45:00-04:00,CANF,negative
211469.0,UPDATE: Cipher Pharmaceuticals Acquires Canadian Rghts to CF101,2015-03-23 07:12:00-04:00,CANF,neutral
211470.0,Can-Fite Signs Multi-Million Dollar Distribution Agreement for CF101 in Canada with Cipher Pharmaceuticals,2015-03-23 07:03:00-04:00,CANF,positive
211471.0,Can-Fite Reports Upcoming '15 Clinical Milestones for Drug Pipeline,2015-01-06 07:23:00-05:00,CANF,neutral
211472.0,Can-Fite Completes Design of Rheumatoid Arthritis Phase III Study of CF101,2014-12-30 07:16:00-05:00,CANF,neutral
211473.0,Can Fite Announces Approval from Regulatory Authorities in Bulgaria to Initiate Enrollment for Phase II Clinical Study in Glaucoma,2014-12-15 07:11:00-05:00,CANF,positive
211474.0,Can-Fite to Initiate Development Program of CF602,2014-12-09 07:12:00-05:00,CANF,neutral
211475.0,UPDATE: Can-Fite Announces $8M At-The-Market Registered Direct Offering,2014-12-02 17:55:00-05:00,CANF,neutral
211476.0,Can-Fite BioPharma Announces $8M At-The-Market Registered Direct Offering,2014-12-02 17:52:00-05:00,CANF,neutral
211477.0,Morning Market Movers,2014-12-01 09:39:00-05:00,CANF,neutral
211478.0,F-3 from Can-fite Biopharma Shows Registration for $50M Mixed Securities Shelf Offering,2014-09-30 16:27:00-04:00,CANF,positive
211479.0,Morning Market Movers ,2014-07-11 09:40:00-04:00,CANF,neutral
211480.0,Morning Market Movers ,2014-07-10 09:42:00-04:00,CANF,neutral
211481.0,Can-Fite's OphthaliX Provides Update on Clinical Developments and Strategic Plans ,2014-06-09 07:14:00-04:00,CANF,neutral
211482.0,From Earlier: Can-Fite Says FDA has Agreed with its Phase II Liver Cancer Protocol ,2014-06-02 09:56:00-04:00,CANF,negative
211483.0,Can-Fite Submits Protocol to U.S. FDA for Phase II Liver Cancer Study,2014-04-29 07:24:00-04:00,CANF,negative
211484.0,‏Can-Fite Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel ,2014-03-17 07:04:00-04:00,CANF,positive
211485.0,Can-Fite Completes $5 M Private Placement,2014-03-10 12:46:00-04:00,CANF,neutral
211486.0,Can Fite Biopharma Shares Halted News Pending,2014-03-10 12:05:00-04:00,CANF,positive
211487.0,Stocks Hitting 52-Week Lows,2013-12-30 10:37:00-05:00,CANF,negative
211488.0,Morning Market Losers ,2013-12-30 10:24:00-05:00,CANF,negative
211489.0,"Stocks To Watch For December 30, 2013",2013-12-30 06:09:00-05:00,CANF,neutral
211490.0,Can-Fite Subsidiary OphthaliX Announces Phase III Study with CF101 for Dry Eye Syndrome did Not Meet Primary Efficacy Endpoint,2013-12-30 05:52:00-05:00,CANF,neutral
211491.0,Morning Market Movers ,2013-12-23 09:55:00-05:00,CANF,neutral
211492.0,Can-Fite BioPharma Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis Met Primary Endpoints ,2013-12-23 07:11:00-05:00,CANF,neutral
211493.0,Can-Fite Anticipates Results from Rheumatoid Arthritis and Dry Eye Syndrome Trials by Year End,2013-12-05 07:09:00-05:00,CANF,neutral
